Skip to main content
SpringerLink
Log in

Hodgkin’s Disease

  • Chapter
Current Cancer Therapeutics

  • 130 Accesses

Abstract

Hodgkin’s disease is uncommon. The annual incidence is two per 100,000 people in the United States, accounting for about 14% of all newly diagnosed lymphomas. In developed countries, there is a bimodal age distribution with one peak in the late 20s and a second peak after age 45 years [1,2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Medeiros L, Greiner T: Hodgkin’s disease. Cancer 1995, 75: 357–369.

    Article  PubMed  CAS  Google Scholar 

  2. MacMahon B: Epidemiological evidence of the nature of Hodgkin’s disease. Cancer 1957, 10: 1045–1054.

    Article  PubMed  CAS  Google Scholar 

  3. Harris N, Jaffe E, Diebold J, et al.: World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17: 3835–3849.

    PubMed  CAS  Google Scholar 

  4. Lister TA, Crowther D, Sutcliffe SB, et al.: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989, 7: 1630–1636.

    PubMed  CAS  Google Scholar 

  5. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998, 339: 1506–1514.

    Article  PubMed  CAS  Google Scholar 

  6. Vijayakumar S, Myrianthopoulos L: An updated dose-response analysis in Hodgkin’s disease. Radiother Oncol 1992, 24: 1–13.

    Article  PubMed  CAS  Google Scholar 

  7. Longo DL, Young RC, Wesley M, et al.: Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 1986, 4: 1295–1306.

    PubMed  CAS  Google Scholar 

  8. Bonadonna G, Santoro A, Gianni AM, et al.: Primary and salvage chemotherapy in advanced Hodgkin’s disease: the Milan Cancer Institute experience. Ann Oncol 1991, 1: 9–16.

    Article  Google Scholar 

  9. Canellos GP, Anderson JR, Propert KJ, et al.: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327: 1478–1484.

    Article  PubMed  CAS  Google Scholar 

  10. Santoro A, Bonfante V, Viviani S, et al.: Decrease in mortality rate by Hodgkin’s disease after ABVD vs MOPP: 10-year results. Proc ASCO 1991, 10: 281.

    Google Scholar 

  11. Somers R, Carde P, Henry-Amar M, et al.: A randomized study in stage IIIB and IV Hodgkin’s disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994, 12: 279–287.

    PubMed  CAS  Google Scholar 

  12. Connors JM, Klimo P, Adams G, et al.: Treatment of advanced Hodgkin’s disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997, 15: 1638–1645.

    PubMed  CAS  Google Scholar 

  13. Viviani S, Bonadonna G, Santoro A, et al.: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol 1996, 14: 1421–1430.

    PubMed  CAS  Google Scholar 

  14. Glick J, Tsiatis A, Schilsky R, et al.: A randomized phase III trial of MOPP/ABV hybrid vs sequential MOPP/ABVD in advanced Hodgkin’s disease: preliminary results of the Intergroup trial. Proc ASCO 1991, 10: 271.

    Google Scholar 

  15. Duggan D, Petroni G, Johnson J, et al.: MOPP/ABV versus ABVD for advanced Hodgkin’s disease: a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol 1997 16: 5a.

    Google Scholar 

  16. Horning S, Hoppe R, Breslin S, et al.: Brief chemotherapy (Stanford V) and involved field radiotherapy are highly effective for advanced Hodgkin’s disease. Proc ASCO 1998, 17: 16.

    Google Scholar 

  17. Diehl V, Franklin J, Tesch H, et al.: Dose escalation of BEACOPP chemotherapy for advanced Hodgkin’s disease in the HD9 trial of the German Hodgkin’s Study Group (GHSG). Proc ASCO 2000, 19: 4.

    Google Scholar 

  18. Tesch H, Sieber M, Ruffer J, et al.: Second interim analysis of the HD7 trial of the GHSG: 2 cycles ABVD plus extended field radiotherapy is more effective than radiotherapy alone in early stage HD. Proc ASH 1999, 94: 268.

    Google Scholar 

  19. Rueda A, Alba E, Ribelles N, et al.: Six cycles of ABVD in the treatment of stage I and II Hodgkin’s lymphoma: a pilot study. J Clin Oncol 1997, 15: 1118–1122.

    PubMed  CAS  Google Scholar 

  20. Horning S, Hoppe R, Breslin S, et al.: Very brief (8 week) chemotherapy and low dose (30 Gy) radiotherapy for limited stage Hodgkin’s disease: preliminary results of the Stanford-Kaiser G4 study of Stanford V + RT. Proc ASH 1999, 94: 387.

    Google Scholar 

  21. Rapoport AP, Rowe JM, Kouides PA, et al.: One hundred autotransplants for relapsed or refractory Hodgkin’s disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993, 11: 2351–2361.

    PubMed  CAS  Google Scholar 

  22. Anderson JE, Litzow MR, Appelbaum FR, et al.: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 1993, 11: 2342–2350.

    PubMed  CAS  Google Scholar 

  23. Armitage J: Early bone marrow transplantation in Hodgkin’s disease. Ann Oncol 1994, 5: 161–163.

    Article  PubMed  Google Scholar 

  24. Weaver CH, Petersen FB, Appelbaum FR, et al.: High-dose fractionated total-body irradiation, etoposide, and cylcophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994, 12: 2559–2566.

    PubMed  CAS  Google Scholar 

  25. Reece DE, Connors JM, Spinelli JJ, et al.: Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood 1994, 83: 1193–1199.

    PubMed  CAS  Google Scholar 

  26. Schmitz N, Sextro M, Pfistner B, et al.: High dose therapy followed by hematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin’s disease: final results of a randomized GHSG and EBMT trial (HD-R1). Proc ASCO 1999, 18: 2.

    Google Scholar 

  27. Yuen AR, Rosenberg SA, Hoppe RT, et al.: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease. Blood 1997, 89: 814–822.

    PubMed  CAS  Google Scholar 

  28. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al.: Leukemia risk following Hodgkin’s disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994, 12: 1063–1073.

    PubMed  Google Scholar 

  29. Biti G, Cellai E, Magrini S, et al.: Second solid tumors and leukemia after treatment for Hodgkin’s disease: an analysis of 1121 patients from a single institution. Int J Radiation Oncol Biol Biophysics 1994, 29: 25–31.

    Article  CAS  Google Scholar 

  30. Dietrich PY, Henry-Amar M, Cosset JM, et al.: Second primary cancers in patients continuously disease-free from Hodgkin’s disease: a protective role for the spleen? Blood 1994, 84: 1209–1215.

    PubMed  CAS  Google Scholar 

  31. Hudson B, Hudson V, Linch D, Anderson L: Late mortality in young BNLI patients cured of Hodgkin’s disease. Ann Oncol 1994, 5: 65–66.

    Article  Google Scholar 

  32. Sankila R, Garwicz S, Olsen JH, et al.: Risk of subsequent malignant neoplasms among 1641 Hodgkin’s disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. J Clin Oncol 1996, 14: 1442–1446.

    PubMed  CAS  Google Scholar 

  33. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al.: Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 1994, 112: 312–325.

    Google Scholar 

  34. Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 1993, 85: 25–31.

    Article  PubMed  CAS  Google Scholar 

  35. Mauch PM, Kalish LA, Marcus KC, et al.: Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin’s disease: long-term analysis of risk factors and outcome. Blood 1996, 87: 3625–3632.

    PubMed  CAS  Google Scholar 

  36. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 1993, 11: 1208–1215.

    PubMed  CAS  Google Scholar 

  37. Viviani S, Ragni G, Santoro A, et al.: Testicular dysfunction in Hodgkin’s disease before and after treatment. Eur J Cancer 1991, 27: 1389–1392.

    Article  PubMed  CAS  Google Scholar 

  38. Mah K, Keane T, Van Dyk J, et al.: Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation-induced lung damage- a prospective clinical study. Int J Radiation Oncol Bial Biophysics 1994, 28: 563–574.

    Article  CAS  Google Scholar 

  39. Horning SJ, Adhikari A, Rizk N, et al.: Effect of treatment for Hodgkin’s disease on pulmonary function: results of a prospective study. J Clin Oncol 1994, 12: 297–305.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Alan R. Yuen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra J. Horning
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Yuen, A.R., Horning, S.J. (2001). Hodgkin’s Disease. In: Current Cancer Therapeutics. Current Medicine Group, London. https://doi.org/10.1007/978-1-4613-1099-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1099-0_18

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-57340-176-0

  • Online ISBN: 978-1-4613-1099-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation